Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

N4-acetylcytidine modification bridges metabolic reprogramming and immune evasion in cancer: mechanisms and therapeutic implications.

Frontiers in immunology·2026
Same author

Navigating the Redox Precipice: Metabolic Gatekeeping as a Therapeutic Window in Pancreatic Precancer.

Frontiers in bioscience (Landmark edition)·2026
Same author

The tumor-nerve-immune electrical axis: A hypothesis-generating framework for electrochemical communication in cancer.

Biochimica et biophysica acta. Molecular basis of disease·2026
Same author

The mechano-immunological landscape in the tumor microenvironment: From mechanical sensing to a new therapeutic paradigm.

Materials today. Bio·2026
Same author

The astrocytic connectome: Gap-Junction topology beyond diffuse syncytium.

Trends in cell biology·2026
Same author

Targeting the Calcineurin Homologous Protein 1 (CHP1)-Transmembrane Protein 87A (TMEM87A) mechanosensing complex: a druggable vulnerability in metastatic ovarian cancer.

Molecular biomedicine·2026

Related Experiment Video

Updated: Feb 18, 2026

Creating Matched In vivo/In vitro Patient-Derived Model Pairs of PDX and PDX-Derived Organoids for Cancer Pharmacology Research
04:49

Creating Matched In vivo/In vitro Patient-Derived Model Pairs of PDX and PDX-Derived Organoids for Cancer Pharmacology Research

Published on: May 5, 2021

7.1K

Organoids: An intermediate modeling platform in precision oncology.

Ming-Zhu Jin1, Run-Run Han2, Guan-Zhong Qiu3

  • 1Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, PR China.

Cancer Letters
|November 28, 2017
PubMed
Summary

Organoid technology offers a powerful 3D in vitro model for cancer research, accurately recapitulating tumor heterogeneity and microenvironment for drug testing and precision medicine applications.

Keywords:
3D culture technologyCancerOrganoidsPrecision oncologyTumor heterogeneity

More Related Videos

Modeling Oral-Esophageal Squamous Cell Carcinoma in 3D Organoids
10:43

Modeling Oral-Esophageal Squamous Cell Carcinoma in 3D Organoids

Published on: December 23, 2022

4.1K
Author Spotlight: Establishment of Pancreatic Cancer-Derived Tumor Organoids and Fibroblasts From Fresh Tissue
07:31

Author Spotlight: Establishment of Pancreatic Cancer-Derived Tumor Organoids and Fibroblasts From Fresh Tissue

Published on: May 26, 2023

6.1K

Related Experiment Videos

Last Updated: Feb 18, 2026

Creating Matched In vivo/In vitro Patient-Derived Model Pairs of PDX and PDX-Derived Organoids for Cancer Pharmacology Research
04:49

Creating Matched In vivo/In vitro Patient-Derived Model Pairs of PDX and PDX-Derived Organoids for Cancer Pharmacology Research

Published on: May 5, 2021

7.1K
Modeling Oral-Esophageal Squamous Cell Carcinoma in 3D Organoids
10:43

Modeling Oral-Esophageal Squamous Cell Carcinoma in 3D Organoids

Published on: December 23, 2022

4.1K
Author Spotlight: Establishment of Pancreatic Cancer-Derived Tumor Organoids and Fibroblasts From Fresh Tissue
07:31

Author Spotlight: Establishment of Pancreatic Cancer-Derived Tumor Organoids and Fibroblasts From Fresh Tissue

Published on: May 26, 2023

6.1K

Area of Science:

  • Oncology
  • Biotechnology
  • 3D cell culture

Background:

  • Cancer exhibits significant heterogeneity and plasticity, complicating research.
  • Current models like cell lines and patient-derived tumor xenografts (PDTXs) have limitations.
  • Organoids provide a more accurate in vitro model compared to traditional cell lines.

Purpose of the Study:

  • To review the translational applications of organoid technology in tumor research.
  • To compare organoids with cell lines and PDTXs regarding advantages and limitations.
  • To discuss the future outlook of organoid technology in precision medicine.

Main Methods:

  • Utilizing three-dimensional in vitro culture of self-organizing stem cells.
  • Recapitulating tumor heterogeneity and microenvironment in a controlled setting.
  • Employing organoids as an intermediate model for tumorigenesis and metastasis studies.

Main Results:

  • Organoids closely mimic tumor heterogeneity and microenvironment.
  • Organoids are more cost-effective and less time-consuming than PDTXs.
  • Organoids serve as effective platforms for drug testing and are stored as living biobanks.

Conclusions:

  • Organoid technology is a valuable tool for advancing tumor research and precision medicine.
  • Organoids offer a superior alternative to cell lines and a more practical option than PDTXs.
  • The future of organoids in oncology holds significant promise for personalized treatments.